A Phase 4 interventional study of Filgrastim in Severe Chronic Neutropenia, sponsored by Sandoz. Terminated at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-28.
Sponsored by Sandoz (formerly part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Purpose of the study is to investigate the safety, immunogenicity and the efficacy of Zarzio®/Filgrastim HEXAL® under chronic administration for 12 months in patients diagnosed with severe chronic neutropenia.
This was a prospective, open-label, non-comparative study. Eligible patients with Severe Chronic Neutropenia received Zarzio® for 12 months. Study visits were scheduled for screening, start of treatment with Zarzio®/Filgrastim HEXAL®, 6 weeks after start of treatment and at months 3, 6, 9 and 12.
Immunogenicity assessment: Patients were screened for anti-recombinant human granulocyte colony stimulating factor (rhG-CSF) antibodies at screening (Visit 01) and at every study visit with the exception of Visit 02 (start of treatment). The evaluation of the immune response to rhG-CSF administration was made by a three-step procedure comprising a validated binding antibody screening and confirmatory radioimmunoprecipitation assay (RIP). Samples positive for binding antibodies in the confirmatory RIP assay were evaluated for neutralizing antibodies using a validated cell-based neutralization antibody assay (NAB).
Efficacy: Complete blood counts with differential white blood cell counts were performed and absolute neutrophil count (ANC) were calculated at every study visit. For each time point the neutrophil counts are summarized by the SAF set using descriptive statistics for the ANC as well as for the changes from baseline.
Safety: Adverse events are listed for the safety population set (SAF) (term, date of AE onset, date of AE resolved, AE duration, severity grade, relationship to study drug, action taken, SAE). Additionally, the following variables were also listed: Serum human chorionic gonadotropin (hCG) pregnancy test, Physical examination, vital signs (pulse, blood pressure), weight (kg), height (cm), Laboratory (hematology, clinical chemistry, urinalysis) values
Sandoz is the lead sponsor of 139 studies on the registry; none are open to participants now.
Of its 11 completed or terminated interventional studies of FDA-regulated products, 6 (55%) have results posted.
First submitted before Sandoz left Novartis.
Counted across the registry records on this site, refreshed daily.
Inclusion criteria:
Exclusion criteria:.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Zarzio®/Filgrastim HEXAL® was administered according to Summary of Product Characteristics (SmPC). It was provided as solution for injection in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU).
Biological: Filgrastim
Zarzio®/Filgrastim HEXAL® solution for injection was provided in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU). Dosage and duration for each patient is as per the recommendations in the SmPC.
Also known as: Zarzio®/Filgrastim HEXAL®, EP2006, rhG-CSF
Incidence of Anti- Recombinant Human Granulocyte Colony Stimulating Factor (rhG-CSF) Antibodies
Incidence of anti-rhG-CSF antibodies was monitored. Patients were screened for anti-rhG-CSF antibodies at screening and at each study except visit 02 (start of treatment = baseline). Evaluation of immune response to rhG-CSF administration was made by a three-step procedure comprising a validated binding antibody screening and confirmatory radioimmunoprecipitation assay (RIP) and a validated cell-based neutralization antibody assay (NAB).
Time frame: screening, 3, 6, 9 and 12 months
Number of Participants With Adverse Events (AEs)
Patients experiencing AEs by system organ class and preferred term (PT) and number of events. Patients with more than one AE coded to the same PT were counted once per PT
Time frame: 12 months
Change in Absolute Neutrophile Count (ANC)
To evaluate the efficacy of Zarzio®/Filgrastim HEXAL® in patients with SCN in terms of changes in absolute neutrophile count (ANC). Change from each visit to baseline in ANC for all patients is calculated.
Time frame: Participants were followed for a duration of 12 months and ANC was assessed at baseline, week 6, Month 3, Month 6, Month 9 and Month 12.
First patient in: 05-Jul-2011, last patient in: 12-Feb-2013. 2 sites (medical school and university hospital)
| Milestone | Zarzio®/Filgrastim HEXAL® (EP2006) |
|---|---|
| Started | 6 |
| Completed | 6 |
| Not completed | 0 |
Incidence of anti-rhG-CSF antibodies was monitored. Patients were screened for anti-rhG-CSF antibodies at screening and at each study except visit 02 (start of treatment = baseline). Evaluation of immune response to rhG-CSF administration was made by a three-step procedure comprising a validated binding antibody screening and confirmatory radioimmunoprecipitation assay (RIP) and a validated cell-based neutralization antibody assay (NAB).
| participants | Zarzio®/Filgrastim HEXAL® |
|---|---|
| Visit 1 - negative | 6 |
| Visit 3 - negative | 5 |
| Visit 4 - negative | 6 |
| Visit 5 - negative | 6 |
| Visit 6 - negative | 6 |
| Visit 7 - negative | 6 |
Patients experiencing AEs by system organ class and preferred term (PT) and number of events. Patients with more than one AE coded to the same PT were counted once per PT
| participants | Zarzio®/Filgrastim HEXAL® |
|---|---|
| Number of Participants With Adverse Events (AEs) | 6 |
To evaluate the efficacy of Zarzio®/Filgrastim HEXAL® in patients with SCN in terms of changes in absolute neutrophile count (ANC). Change from each visit to baseline in ANC for all patients is calculated.
| 10^9 cells/L | Zarzio®/Filgrastim HEXAL® |
|---|---|
| ANC Visit 1 Screening to Baseline (Visit 2) | -1.252 (-10.90 to 2.84) |
| ANC Visit 3 Week 6 to Baseline (Visit 2) | 6.873 (-11.20 to 16.40) |
| ANC Visit 4 Month 3 to Baseline (Visit 2) | -0.198 (-11.00 to 25.50) |
| ANC Visit 5 Month 6 to Baseline (Visit 2) | -0.711 (-10.80 to 12.38) |
| ANC Visit 6 Month 9 to Baseline (Visit 2) | 1.506 (-9.60 to 14.70) |
| ANC Visit 7 Month 12 to Baseline (Visit 2) | 1.579 (-10.80 to 18.87) |
Collected over 12 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Open-label Zarzio®/Filgrastim HEXAL® | — | 1/6 (16.7%) | 6/6 (100%) |
| Event | Open-label Zarzio®/Filgrastim HEXAL® |
|---|---|
| NephrolithiasisRenal and urinary disorders | 1/6 |
| Event | Open-label Zarzio®/Filgrastim HEXAL® |
|---|---|
| NasopharyngitisInfections and infestations | 3/6 |
| HeadacheNervous system disorders | 3/6 |
| FatigueGeneral disorders | 2/6 |
| Genital infection fugalInfections and infestations | 1/6 |
| GingivitisInfections and infestations | 1/6 |
| Groin abscessInfections and infestations | 1/6 |
| Herpes virus infectionInfections and infestations | 1/6 |
| Mucosal infectionInfections and infestations | 1/6 |
| Oral herpesInfections and infestations | 1/6 |
| PneumoniaInfections and infestations | 1/6 |
Intent-to treat (ITT): All patients with at least one dose EP2006. Safety population (SAF): ITT and at least one post-baseline safety assessment. Immunogenicity population: ITT and at least one available anti-rhG-CSF antibody assessment. No patient was excluded of any of the populations. Results presented for SAF.
| Age, Continuous(years) | Zarzio®/Filgrastim HEXAL® |
|---|---|
| Median | 45.0 (27 to 77) |
| Sex: Female, Male(Participants) | Zarzio®/Filgrastim HEXAL® |
|---|---|
| Female | 5 |
| Male | 1 |
| Race/Ethnicity, Customized(participants) | Zarzio®/Filgrastim HEXAL® |
|---|---|
| Caucasian | 5 |
| Latin American | 1 |
| Region of Enrollment(participants) | Zarzio®/Filgrastim HEXAL® |
|---|---|
| Sweden | 4 |
| Germany | 2 |
| Severe Chronic Neutropenia (SCN) diagnosis(participants) | Zarzio®/Filgrastim HEXAL® |
|---|---|
| Congenital neutropenia | 1 |
| Cyclic neutropenia | 1 |
| Idiopathic neutropenia | 4 |
| Granulocyte Colony Stimulating Factor (G-CSF) pretreatment(participants) | Zarzio®/Filgrastim HEXAL® |
|---|---|
| Yes | 6 |
| No | 0 |
| Height(cm) | Zarzio®/Filgrastim HEXAL® |
|---|---|
| Median | 165.0 (159 to 174) |
| Weight(kg) | Zarzio®/Filgrastim HEXAL® |
|---|---|
| Median | 67.0 (55 to 98) |
Plan to share: Yes — Since there are only six patients enrolled, all the patient data is already provided in the registry.
The record gives a start of Jul 2011, a primary completion of Mar 2014 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 2 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Filgrastim
Neutropenia, severe chronic